The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model

Journal of Veterinary Pharmacology and Therapeutics

Volumn 30, Issue 4, 2007, Pages 281-287

  De La Puente Redondo, V ^a   Tingley III, F D ^b   Schneider, R P ^b   Hickman, M A ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIEMETIC AGENT; CERENIA; CJ 11972; CJ 18 518; DRUG METABOLITE; MAROPITANT; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG SELECTIVITY; EXPERIMENTAL MODEL; GERBIL; LEG MOVEMENT; MALE; NONHUMAN; PRIORITY JOURNAL; TIME;

ANIMALS; ANTIEMETICS; BRAIN; DOGS; GERBILLINAE; MALE; MODELS, ANIMAL; MOTOR ACTIVITY; QUINUCLIDINES; RECEPTORS, NEUROKININ-1;

CANIS FAMILIARIS; GERBILLINAE;

EID: 34347371789     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2007.00847.x     Document Type: Article

References (39)

1. Andrews, P.L.R., Kovacs, M. Watson, J.W. (2001) The anti-emetic action of the neurokinin1 receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog. Neuroscience Letters, 314, 102 104.
2. Bakowski, M.T. (1984) Advances in anti-emetic therapy. Cancer Treatment Reviews, 11, 237 256.
3. Bountra, C., Bunce, K., Dale, T., Gardner, C., Jordan, C., Twissell, D. Ward, P. (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. European Journal of Pharmacology, 249, R3 4.
4. Bristow, L.J. Young, L. (1994) Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. European Journal of Pharmacology, 253, 245 252.
5. Carpenter, D.O., Briggs, D.B. Strominger, N. (1983) Responses of neurons of canine area postrema to neurotransmitters and peptides. Cellular and Molecular Neurobiology, 3, 113 126.
6. Chapman, R.W., Schilling, A., Ng, K., Nardo, C., Kreutner, W. Young, S. (1999) Combined NK(1) and NK(2) receptor antagonists on the bronchoconstrictor response to NKA in dogs. Pulmonary Pharmacology & Therapeutics, 12, 261 266.
7. Diemunsch, P. Grelot, L. (2000) Potential of substance P antagonists as antiemetics. Drugs, 60, 533 546.
8. Doi, T., Kamo, I., Imai, S., Okanishi, S., Ishimaru, T., Ikeura, Y. Natsugari, H. (1999) Effects of TAK-637, a tachykinin receptor antagonist, on lower urinary tract function in the guinea pig. European Journal of Pharmacology, 383, 297 303.
9. Fukuda, H., Koga, T., Furukawa, N., Nakamura, E. Shiroshita, Y. (1999) The tachykinin NK1 receptor antagonist GR205171 abolishes the retching activity of neurons comprising the central pattern generator for vomiting in dogs. Neuroscience Research, 33, 25 32.
10. Gardner, C.J., Twissell, D.J. Dale, T.J. (1995) The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. British Journal of Pharmacology, 116, 3158 3163.
11. Gardner, C.J., Armour, D.R., Beattie, D.T., Gale, J.D., Hawcock, A.B., Kilpatrick, G.J., Twissell, D.J. Ward, P. (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regulatory Peptides, 65, 45 53.
12. Hagan, R.M., Ireland, S.J., Jordan, C.C., Beresford, I.J.M., Deal, M.J. Ward, P. (1991) Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function. Neuropeptides, 19, 127 135.
13. Hesketh, P.J., Van Belle, S., Aapro, M., Tattersall, F.D., Naylor, R.J., Hargreaves, R., Carides, A.D., Evans, J.K. Horgan, K.J. (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. European Journal of Cancer, 39, 1074 1080.
14. Koch, K.L. (1995) Approach to the patient with nausea and vomiting, chapter 33. In Textbook of Gastroenterology, 2nd edn, Vol. 1. Ed. Yamada, T., pp. 731 749. JB Lippincott Co., Philadelphia, PA.
15. Leslie, R.A. Reynolds, D.J.M. (1992) Functional anatomy of the emetic circuitry in the brainstem. In Mechanisms and Control of Emesis. Eds Bianch, A.L., Grelot, L., Miller, A.D. King, G.L., pp. 19 27. Colloque INSERM, John Libbey Eurotext Ltd, Collioure, France.
16. Lucot, J.B., Obach, R.S., McLean, S. Watson, J.W. (1997) The effect of CP-99994 on the responses to provocative motion in the cat. British Journal of Pharmacology, 120, 116 120.
17. Maggi, C.A. (1995) The mammalian tachykinin receptors. General Pharmacology, 26, 911 944.
18. Mantyh, P.W. (2002) Neurobiology of substance P and the NK1 receptor. Journal of Clinical Psychiatry, 63, 6 10.
19. McLean, S., Ganong, A., Seymour, P.A., Snider, R.M., Desai, M.C., Rosen, T., Bryce, D.K., Longo, K.P., Reynolds, L.S., Robinson, G., Schmidt, A.W., Siok, C. Heym, J. (1993) Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. Journal of Pharmacology and Experimental Therapeutics, 267, 472 479.
20. McLean, S., Ganong, A., Seymour, P.A., Bryce, D.K., Crawford, R.T., Morrone, J., Reynolds, L.S., Schmidt, A.W., Zorn, S., Watson, J., Fossa, A., DePasquale, M., Rosen, T., Nagahisa, A., Tsuchiya, M. Heym, J. (1996) Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. Journal of Pharmacology and Experimental Therapeutics, 277, 900 908.
21. Patel, L. Lindley, C. (2003) Aprepitant-a novel NK1-receptor antagonist. Expert Opinion on Pharmacotherapy, 4, 2279 2296.
22. Quartara, L. Maggi, C.A. (1997) The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides, 31, 537 563.
23. Quartara, L. Maggi, C.A. (1998) The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides, 32, 1 49.
24. Rudd, J.A., Jordan, C.C. Naylor, R.J. (1996) The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. British Journal of Pharmacology, 119, 931 936.
25. Rupniak, N.M.J. Williams, A.R. (1994) Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. European Journal of Pharmacology, 265, 179 183.
26. Rupniak, N.M.J., Tattersall, F.D., Williams, A.R., Rycroft, W., Carlson, E.J., Cascieri, M.A., Sadowski, S., Ber, E., Hale, J.J., Mills, S.G., MacCross, M., Seward, E., Huscroft, I., Owen, S., Swain, C.J., Hill, R.G. Hargreaves, R.J. (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. European Journal of Pharmacology, 326, 201 209.
27. Sachais, B.S., Snider, R.M., Lowe, J.A. III. Krause, J.E. (1993) Molecular basis for the species selectivity of the substance P antagonist CP-96,345. The Journal of Biological Chemistry, 268, 2319 2323.
28. Saria, A. (1999) The tachykinin NK1 receptor in the brain: pharmacology and putative functions. European Journal of Pharmacology, 375, 51 60.
29. Shaikh, M.B., Steinberg, A. Siegel, A. (1993) Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behaviour in the cat. Brain Research, 625, 283 294.
30. Singh, L., Field, M.J., Hughes, J., Kuo, B.-S., Suman-Chauhan, N., Tuladhar, B.R., Wright, D.S. Naylor, R.J. (1997) The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. European Journal of Pharmacology, 321, 209 216.
31. Smith, B.J., Doran, A.C., McLean, S., Tingley, F.D. III., O'Neill, B.T. Kajiji, S.M. (2001) P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics, 298, 1252 1259.
32. Strader, C.D., Fong, T.M., Tota, M.R., Underwood, D. Dixon, R.A.F. (1994) Structure and function of G protein-coupled receptors. Annual Review of Biochemistry, 63, 101 132.
33. Tattersall, F.D., Rycroft, W., Hargreaves, R.J. Hill, R.G. (1993) The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. European Journal of Pharmacology, 250, R5 6.
34. Tattersall, F.D., Rycroft, W., Francis, B., Pearce, D., Merchant, K., MacLeod, A.M., Ladduwahetty, T., Keown, L., Swain, C., Baker, R., Cascieri, M., Ber, E., Metzger, J., MacIntyre, D.E., Hill, R.G. Hargreaves, R.J. (1996) Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35, 1121 1129.
35. Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G.R. De Ponti, F. (2004) Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Alimentary Pharmacology and Therapeutics, 19, 379 390
36. Tsuchiya, M., Fujiwara, Y., Kanai, Y., Mizutani, M., Shimada, K., Suga, O., Ueda, S., Watson, J.W. Nagahisa, A. (2002) Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology, 66, 144 152.
37. Washabau, R.J. Elie, M.S. (1995) Antiemetic therapy. In Kirk's Current Veterinary Therapy XII. Ed. Bonagura, J.D., pp. 679 684. W. B. Saunders, Philadelphia, PA.
38. Watson, J.W., Gonsalves, S.F., Fossa, A.A., McLean, S., Seeger, T., Obach, S. Andrews, P.L.R. (1995) The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. British Journal of Pharmacology, 115, 84 94.
39. Yates, B.J., Miller, A.D. Lucot, J.B. (1998) Physiological basis and pharmacology of motion sickness: an update. Brain Research Bulletin, 47, 395 406.